Hot Features
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, typ... Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.0698 | 0.0698 | 0.0698 | 2500 | 0.0698 | CS |
| 4 | 0.0008 | 1.15942028986 | 0.069 | 0.0744 | 0.0492 | 55342 | 0.07144085 | CS |
| 12 | 0.002 | 2.94985250737 | 0.0678 | 0.08784 | 0.0492 | 25951 | 0.07279204 | CS |
| 26 | -0.004 | -5.42005420054 | 0.0738 | 0.098 | 0.0492 | 24105 | 0.07382851 | CS |
| 52 | 0.0396 | 131.125827815 | 0.0302 | 0.2102 | 0.025 | 26683 | 0.07919413 | CS |
| 156 | -0.0102 | -12.75 | 0.08 | 0.2102 | 0.023 | 21707 | 0.06457699 | CS |
| 260 | -0.6882 | -90.7915567282 | 0.758 | 0.758 | 0.023 | 27090 | 0.16561256 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.